Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 92 filers reported holding Y-MABS THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $100 | -20.0% | 18,282 | 0.0% | 0.00% | – |
| Q2 2023 | $125 | +0.8% | 18,282 | -26.1% | 0.00% | – |
| Q1 2023 | $124 | +44.2% | 24,723 | +40.3% | 0.00% | – |
| Q4 2022 | $86 | -100.0% | 17,623 | +5.5% | 0.00% | – |
| Q3 2022 | $241,000 | +10.6% | 16,708 | +15.8% | 0.00% | – |
| Q2 2022 | $218,000 | +29.8% | 14,423 | +1.8% | 0.00% | – |
| Q1 2022 | $168,000 | -99.2% | 14,165 | -98.3% | 0.00% | -100.0% |
| Q3 2019 | $21,833,000 | +27.6% | 837,800 | +12.0% | 0.00% | +50.0% |
| Q2 2019 | $17,115,000 | +2.0% | 748,351 | +16.9% | 0.00% | 0.0% |
| Q1 2019 | $16,782,000 | +111.8% | 640,297 | +64.4% | 0.00% | +100.0% |
| Q4 2018 | $7,922,000 | -23.4% | 389,497 | +0.0% | 0.00% | -50.0% |
| Q3 2018 | $10,342,000 | – | 389,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 191,176 | $2,271,000 | 2.63% |
| Sofinnova Investments, Inc. | 2,194,278 | $26,068,000 | 1.98% |
| MPM BioImpact LLC | 443,702 | $5,271,000 | 1.42% |
| Soleus Capital Management, L.P. | 238,982 | $2,839,000 | 0.37% |
| Lombard Odier Asset Management (Switzerland) SA | 221,774 | $2,635,000 | 0.21% |
| Artal Group S.A. | 400,000 | $4,752,000 | 0.20% |
| Polar Capital Holdings Plc | 2,877,671 | $34,187,000 | 0.15% |
| ASHFORD CAPITAL MANAGEMENT INC | 106,770 | $1,268,000 | 0.14% |
| Cormorant Asset Management, LP | 150,000 | $1,782,000 | 0.14% |
| Virtus ETF Advisers LLC | 23,646 | $281,000 | 0.13% |